INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/GiftVerified data

Muller Lorenz reported MIST

Chief Commercial Officer · Milestone Pharmaceuticals Inc. · Common Shares

Side
G
Value
—
Shares
25.0K
Price
—
Executed
Dec 9, 2025
Disclosed
Dec 11, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Dec 9 executedDec 11, 2025 disclosed

MIST · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
16/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Gift

  • Relative size+5 / 25

    No reported dollar value · 20.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MIST

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DS
    Duty StuartDirector
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    77.0K sh
    		Jun 10, 2026Jun 12, 2026
    traded Jun 10, 2026
    		+2dSEC FORM 4

    Evidence

    5
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    136.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    136.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    NE
    Nelson Jeffrey EdwardChief Operating Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    204.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    204.0K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    36
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    24
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    17
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    62
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$135K
    58.0K sh
    		Dec 15, 2025Jan 28, 2026
    traded Dec 15, 2025
    		+44dSEC FORM 4

    Evidence

    13
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    24
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    62
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$124K
    53.6K sh
    		Dec 15, 2025Jan 28, 2026
    traded Dec 15, 2025
    		+44dSEC FORM 4

    Evidence

    24
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 12, 2025Jan 28, 2026
    traded Dec 12, 2025
    		+47dSEC FORM 4

    Evidence

    17
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    17
    HA
    Hasija AmitCFO & EVP of Corp. Development
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    62
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$135K
    58.0K sh
    		Dec 15, 2025Jan 28, 2026
    traded Dec 15, 2025
    		+44dSEC FORM 4

    Evidence

    9
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Option exercise
    		M—
    20.1K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    36
    BD
    Bharucha DavidChief Medical Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$24K
    12.2K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    36
    ML
    Muller LorenzChief Commercial Officer
    MISTMilestone Pharmaceuticals Inc.
    Open-market sale
    		SELL$22K
    11.2K sh
    		Jan 26, 2026Jan 28, 2026
    traded Jan 26, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001771207-25-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 9, 2025
    Published
    Dec 11, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Muller Lorenz
    Role
    Chief Commercial Officer
    Transaction
    GiftAs filed: “G”
    Asset
    Milestone Pharmaceuticals Inc.
    Ticker
    MIST
    Shares
    25.0K
    Price per share
    $0
    Execution date (reported)
    Dec 9, 2025
    Owned after transaction
    150.1K shares
    Days from execution to publication
    2

    What this establishes

    Muller Lorenz filed this Form 4 reporting a gift of MIST on Dec 9, 2025. It became public on Dec 11, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Muller Lorenzcik:0001771207
    Issuer
    Milestone Pharmaceuticals Inc.cik:0001408443

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.